Previously, Jivi was approved in September 2018 for adults and adolescents aged 12 years and older with this hemophilia subtype. 2 According to data collected from federally funded hemophilia ...

Pfizer's Hympavzi showed superior bleed control in hemophilia A and B patients with inhibitors, reducing bleeding rates and showing good tolerability. ... FDA Approves Sanofi’s Hemophilia Drug.

Hympavzi was one of two Pfizer hemophilia treatments approved by the FDA in 2024. The company has already removed the other—hemophilia B gene therapy Beqvez—from the market, saying it was ...